The Efficacy of Different Triptans for the Treatment of Acute Headache in Pediatric Migraine : A Systematic Review
BACKGROUND: Serotonin receptors 5-HT1B and 5-HT1D in the cerebral arteries are activated by the 5-hydroxytryptophan agonists (triptans) to relieve the discomfort associated with migraines. Even though triptans are often used to treat acute migraines, there is some debate over their effectiveness.
OBJECTIVE: Our systematic review aimed to evaluate the effectiveness of triptans for acute treatment of migraine in young individuals.
METHODS: Utilizing the databases of Google Scholar, Cochrane Library, and PubMed, a literature search was conducted, and all papers published till July 2022 were included. This systematic review was carried out following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards. In addition to the Boolean operators AND, OR, and NOT, the following descriptive terms were also used: "Triptans," "Pediatric Migraine," "Migraine disorders," "Headache," "Children," and "Adolescent.".
RESULTS: A total of 1047 studies were identified, and 25 articles were finally included in the study. 17 of them were RCTs while the remaining were non-randomized trials. Most studies recruited participants aged between 12-17 years. Among 25 studies, 7 reported sumatriptan use, 3 assessed a combination of sumatriptan and naproxen, 4 were on almotriptan, 1 on eletriptan, 6 on rizatriptan, and 4 on zolmitriptan use.
CONCLUSION: We found that rizatriptan (good tolerability profile with a dose of 5 mg) and sumatriptan (nasal spray, 10 mg and 20 mg) had higher efficiency as compared to other triptans. Regardless of type or dose, all triptans are generally well tolerated by patients, but a few adverse effects such as light-headedness (sumatriptan), nasopharyngitis, and, muscular spasms (sumatriptan/ naproxen), somnolence, and dry mouth (rizatriptan), and dizziness (zolmitriptan group) were reported with the triptans.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
Indian pediatrics - 60(2023), 8 vom: 15. Aug., Seite 663-671 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chanchlani, Roshan [VerfasserIn] |
|---|
| Themen: |
2FS66TH3YW |
|---|
| Anmerkungen: |
Date Completed 14.08.2023 Date Revised 13.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM357115597 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357115597 | ||
| 003 | DE-627 | ||
| 005 | 20231226071909.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1190.xml |
| 035 | |a (DE-627)NLM357115597 | ||
| 035 | |a (NLM)37209053 | ||
| 035 | |a (PII)S097475591600542 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chanchlani, Roshan |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Efficacy of Different Triptans for the Treatment of Acute Headache in Pediatric Migraine |b A Systematic Review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.08.2023 | ||
| 500 | |a Date Revised 13.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Serotonin receptors 5-HT1B and 5-HT1D in the cerebral arteries are activated by the 5-hydroxytryptophan agonists (triptans) to relieve the discomfort associated with migraines. Even though triptans are often used to treat acute migraines, there is some debate over their effectiveness | ||
| 520 | |a OBJECTIVE: Our systematic review aimed to evaluate the effectiveness of triptans for acute treatment of migraine in young individuals | ||
| 520 | |a METHODS: Utilizing the databases of Google Scholar, Cochrane Library, and PubMed, a literature search was conducted, and all papers published till July 2022 were included. This systematic review was carried out following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards. In addition to the Boolean operators AND, OR, and NOT, the following descriptive terms were also used: "Triptans," "Pediatric Migraine," "Migraine disorders," "Headache," "Children," and "Adolescent." | ||
| 520 | |a RESULTS: A total of 1047 studies were identified, and 25 articles were finally included in the study. 17 of them were RCTs while the remaining were non-randomized trials. Most studies recruited participants aged between 12-17 years. Among 25 studies, 7 reported sumatriptan use, 3 assessed a combination of sumatriptan and naproxen, 4 were on almotriptan, 1 on eletriptan, 6 on rizatriptan, and 4 on zolmitriptan use | ||
| 520 | |a CONCLUSION: We found that rizatriptan (good tolerability profile with a dose of 5 mg) and sumatriptan (nasal spray, 10 mg and 20 mg) had higher efficiency as compared to other triptans. Regardless of type or dose, all triptans are generally well tolerated by patients, but a few adverse effects such as light-headedness (sumatriptan), nasopharyngitis, and, muscular spasms (sumatriptan/ naproxen), somnolence, and dry mouth (rizatriptan), and dizziness (zolmitriptan group) were reported with the triptans | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Sumatriptan |2 NLM | |
| 650 | 7 | |a 8R78F6L9VO |2 NLM | |
| 650 | 7 | |a zolmitriptan |2 NLM | |
| 650 | 7 | |a 2FS66TH3YW |2 NLM | |
| 650 | 7 | |a rizatriptan |2 NLM | |
| 650 | 7 | |a 51086HBW8G |2 NLM | |
| 650 | 7 | |a Naproxen |2 NLM | |
| 650 | 7 | |a 57Y76R9ATQ |2 NLM | |
| 650 | 7 | |a Tryptamines |2 NLM | |
| 700 | 1 | |a Agrawal, Amit |e verfasserin |4 aut | |
| 700 | 1 | |a Janjua, Dalwinder |e verfasserin |4 aut | |
| 700 | 1 | |a Hafsa, Shaik Nida |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian pediatrics |d 1964 |g 60(2023), 8 vom: 15. Aug., Seite 663-671 |w (DE-627)NLM000375144 |x 0974-7559 |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2023 |g number:8 |g day:15 |g month:08 |g pages:663-671 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 2023 |e 8 |b 15 |c 08 |h 663-671 | ||